Compressed tablets containing Griffonia-derived 5-HTP at 50 mg and 100 mg strengths are produced for immediate-release oral administration by high-shear wet granulation. The raw extract is pre-dried in a vacuum dryer at 40–50 °C to LOD ≤ 3.0% when incoming RH exceeds 60%; lot-to-lot extract particle size D90 shifts from 80 µm to 210 µm and changes binder liquid demand by 10–15%, so granulation endpoint must be adjusted per lot. A typical core formulation contains 20–35% w/w API, microcrystalline cellulose 20–30% w/w, mannitol 20–30% w/w, croscarmellose sodium 2–4% w/w, povidone K30 3–5% w/w, and magnesium stearate 0.5–1.0% w/w. Granulation is performed in a high-shear mixer with impeller tip speed 3–6 m/s and chopper speed 1500–2500 rpm; the wet mass is passed through a 1.0 mm screen and dried in a fluid-bed dryer with inlet air dew point ≤ −10 °C and product temperature 40–45 °C to LOD 1.5–2.5%. Milled granules are compressed on a rotary tablet press with precompression 2–4 kN and main compression 8–14 kN; tablet hardness is maintained at 80–120 N with friability ≤ 0.8% according to USP <1216>. Aqueous film coating is applied in a perforated pan coater with inlet air 70–75 °C, bed temperature 40–45 °C, and pan speed 6–8 rpm to 2.5–3.5% weight gain. Amine-based lubricants or alkalizing agents are excluded from the blend because they accelerate oxidative discoloration of 5-HTP. Dissolution is conducted under USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N HCl, with Q = 80% at 30 min; uniformity of dosage units conforms to USP <905>, and residual solvents are controlled per ICH Q3C. The terminal product is a film-coated immediate-release tablet packaged in HDPE bottles of 30 or 60 counts under 21 CFR 210/211 cGMP.

Why do dosator capsule fillers require granulated 5-HTP rather than raw extract?

In hard gelatin or HPMC capsule filling on dosator-type machines with 0.5–1.0 mm nozzle diameter, raw Griffonia extract with D90 80–200 µm and moisture 4–6% produces plug weight RSD > 5%, which necessitates dry granulation. Roller compaction at 40–60 bar hydraulic pressure and 1.0 mm screen granulation yields granules with Hausner ratio 1.15–1.25; the granulated material is then filled into size 0 or 00 capsules to deliver 50 mg or 100 mg 5-HTP per unit. The fill formulation includes 40–60% w/w mannitol or lactose monohydrate, 3–5% w/w crospovidone, and 0.25–0.5% w/w sodium stearyl fumarate; magnesium stearate is limited to ≤ 0.5% w/w because over-lubrication reduces plug cohesiveness and increases ejection force. In production runs, static charging on HPMC capsules raises fill weight RSD; grounding and humidity control at 45–50% RH reduce rejection rates. Fill weight is monitored by in-process check weighing at 15-min intervals with acceptance limits ± 5% for a 300 mg fill; USP <905> and Ph. Eur. 2.9.5 are applied. Dissolution testing per USP <711> uses Apparatus I at 100 rpm in 900 mL pH 1.2 simulated gastric fluid with Q = 75% at 45 min; capsule shells are tested for moisture uptake at 25 °C / 60% RH and must not exceed 12–14% LOD for gelatin or 4–8% for HPMC to prevent brittleness. The terminal finished product type is hard capsule in PVC/PVDC/Alu blister or HDPE bottle with desiccant.

Effervescent sachet granules and the acid-base buffering boundary

Because residual moisture above 0.5% initiates premature citric acid–sodium bicarbonate reaction, effervescent granules containing 25 mg or 50 mg 5-HTP per 2 g sachet are manufactured by non-aqueous granulation. The base formulation comprises anhydrous citric acid 18–25% w/w, sodium bicarbonate 28–35% w/w, mannitol 25–35% w/w, sodium carbonate 1–3% w/w, and the API at 1.5–3.0% w/w (equivalent to 25–50 mg per 2 g dose). Granulation is carried out in a fluid-bed granulator using 1.0–2.0% w/w PEG 6000 dissolved in isopropanol as binder; inlet air dew point is maintained below −20 °C and product temperature 30–35 °C to avoid acid-base reaction and API oxidation. The process is considered complete when loss on drying is ≤ 0.5% and the granules pass a 2.0 mm sieve while retaining less than 20% fines below 0.5 mm. Dried granules are sized through 1.4 mm sieve and immediately filled into triple-laminate paper/PE/aluminum sachets with moisture vapor transmission rate below 0.05 g/m²/day. Disintegration testing per Ph. Eur. 2.9.1 for effervescent granules requires disintegration within 5 min in 200 mL water at 15–25 °C. Uniformity of mass complies with USP <905> for single-dose preparations, and residual isopropanol is controlled per ICH Q3C Class 3 limits. The terminal finished product type is a single-dose effervescent granule for oral solution, packaged in cold-form aluminum sachets under 35–45% RH fill room conditions.

Extended-release matrix tablets containing 5-HTP at 100 mg or 200 mg strengths use hypromellose K4M and K100M as rate-controlling polymers at 30–50% w/w total matrix former. The drug load is 20–30% w/w with lactose monohydrate or dibasic calcium phosphate dihydrate as filler. Roller compaction is preferred over wet granulation to preserve polymer hydration behavior; ribbons are compacted at 2.5–3.5 mm thickness and milled through 1.0 mm screen. The granules are blended with magnesium stearate 0.5–1.0% w/w and compressed to hardness 150–250 N on a 16-station rotary press. Dissolution profiling per USP <711> Apparatus I at 100 rpm in 900 mL pH 6.8 phosphate buffer requires release of 20–30% at 1 h, 50–65% at 4 h, and ≥ 80% at 12 h. Compliance includes ICH Q6A decision rules for extended-release dissolution and USP <905> for content uniformity. The terminal product type is a film-coated extended-release tablet packaged in amber glass or HDPE bottles to limit photodegradation of 5-HTP.

When lyophilized injection demands reducing sugar-free excipient matrices

In aqueous solution, 5-HTP undergoes oxidative degradation and cannot withstand terminal sterilization; therefore, a stable lyophilized product is prepared from a bulk solution of 5–10 mg/mL 5-HTP in Water for Injection adjusted to pH 2.8–3.5 with 1 M hydrochloric acid. Nitrogen sparging of the bulk solution during compounding minimizes dissolved oxygen; headspace oxygen is maintained below 2% after sealing. Mannitol at 3–5% w/v serves as crystalline bulking agent; trehalose at 1–2% w/v may be added only after compatibility screening because reducing sugars can degrade 5-HTP through Maillard adducts. The solution is sterile-filtered through 0.22 µm PVDF or PES filters into depyrogenated Type I glass vials under ISO 14644-1 Class 5 unidirectional airflow, with EU GMP Annex 1 Grade A/B zoning. Lyophilization cycle for 5 mL fill in 10 mL vials: freezing at −45 °C for 180 min, primary drying at shelf temperature −20 °C and chamber pressure 80–120 mTorr for 18–24 h, secondary drying at 25 °C for 6–8 h to residual moisture 1.0–2.0%. The lyophilized cake is reconstituted with 5 mL WFI to a clear solution; particulate matter per USP <788> must show ≤ 6000 particles ≥ 10 µm and ≤ 600 particles ≥ 25 µm per container. Bacterial endotoxins are controlled to < 0.5 EU/mg per USP <85>, and sterility per USP <71>. Because published multi-lot process validation data for injectable 5-HTP in this specific indication are limited, cycle robustness is confirmed by lyophilization temperature mapping and container closure integrity testing per USP <1207>. The terminal finished product type is a single-dose lyophilized powder for injection, packaged under vacuum or nitrogen headspace in Type I glass vials with butyl rubber stoppers and aluminum seals.

Fluidized-bed spray granulation may be substituted for high-shear wet granulation when granules intended for oral suspension at 100 mg or 200 mg 5-HTP per unit are required. The spray solution contains povidone or hypromellose as binder at 5–7.5% w/w dry solids; the API is pre-dispersed with 2–5% w/w colloidal silicon dioxide to prevent nozzle blockage. The bed is operated at inlet air temperature 60–70 °C, atomizing air pressure 1.5–2.0 bar, and spray rate 20–40 g/min/kg of bed mass; granules are dried to LOD 1.0–2.0% and sieved through 0.8–1.4 mm. In-process particle size is controlled with D50 250–400 µm and bulk density 0.45–0.55 g/cm³. Filling into stick packs occurs at 20–25 °C and 35–45% RH to avoid static charge. Dissolution testing per Ph. Eur. 2.9.3 uses Apparatus II at 50 rpm in 500 mL water at 37 °C, with Q = 80% at 15 min; uniformity of mass complies with USP <905> for single-dose preparations. The terminal finished product type is a single-dose oral granule for solution or suspension, packaged in foil/polyethylene stick packs.